Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $75.00 Average PT from Analysts

by · The Cerbat Gem

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $75.00.

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Barclays started coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. JonesTrading upped their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Mizuho raised their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Finally, Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Get Our Latest Analysis on Enliven Therapeutics

Insider Activity at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. This represents a 13.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 180,831 shares of company stock worth $10,735,269 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. KBC Group NV acquired a new stake in Enliven Therapeutics in the first quarter valued at $38,000. State of Wyoming acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth $96,000. FNY Investment Advisers LLC purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $126,000. WINTON GROUP Ltd acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $228,000. Finally, Squarepoint Ops LLC acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at about $259,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $53.36 on Wednesday. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The firm has a 50-day simple moving average of $56.53 and a 200-day simple moving average of $45.75. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of -31.95 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts forecast that Enliven Therapeutics will post -1.69 EPS for the current year.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. The company applies a precision oncology approach, seeking to create targeted therapies that may offer improved efficacy, safety, durability and convenience compared with existing treatments.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven solid tumors.

Recommended Stories